
TELA Stock Forecast & Price Target
TELA Analyst Ratings
Bulls say
TELA Bio is well-positioned for success in the medical technology sector due to its focus on anatomically conscious soft-tissue reconstruction solutions that prioritize the patient's natural healing response. With a growing portfolio of products specifically designed for various surgical procedures, including hernia repair and abdominal wall reconstruction, TELA Bio has a strong potential for capturing market share and generating long-term revenue. However, the company should be prepared for potential delays and challenges in the regulatory process, as seen with other synthetic mesh manufacturers facing lawsuits. It will be important for TELA Bio to prioritize compliance and maintain strong relationships with regulatory agencies to ensure timely approvals and avoid any negative impact on its operating results.
Bears say
TELA Bio is facing numerous challenges as evidenced by their recent lowered sales outlook, stock performance, and continued strategic restructuring of their US commercial team. This includes a steep deceleration in sales growth and potential disruptions as they implement new sales strategies and ramp up new hires, leading to increased losses and potential dilution for shareholders. Additionally, the company's concentrated product portfolio and heavy reliance on reimbursement for their products limit their diversification and leave them vulnerable to changes in the healthcare landscape. These fundamental reasons contribute to our negative outlook on TELA Bio's stock.
This aggregate rating is based on analysts' research of TELA Bio, Inc. and is not a guaranteed prediction by Public.com or investment advice.
TELA Analyst Forecast & Price Prediction
Start investing in TELA
Order type
Buy in
Order amount
Est. shares
0 shares